Trial reportBMC endocrine disorders2022
Efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients, a randomized controlled trial - "Pharm-MD" : Impact of clinical pharmacists in diabetes care.
Trial report in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03377127 (PHARM-MD; An Open-Label, Randomized Controlled Phase II Study to Evaluate the Efficacy of a Pharmacist Managed Diabetes Clinic in High-Risk Diabetes Patients), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PHARM-MD; An Open-Label, Randomized Controlled Phase II Study to Evaluate the Efficacy of a Pharmacist Managed Diabetes Clinic in High-Risk Diabetes Patients
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Pharmacist-integrated collaborative outpatient care for risk factor control across the cardiovascular-kidney-metabolic spectrum: a systematic review and meta-analysis of randomized trials.Frontiers in medicine · 2026Pooled it
- A mixed-methods approach to understanding pharmacists' experiences with the CANRISK diabetes risk questionnaire and user guide.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2026Article
- Personalized Medicine Interventions for Glycemic Control in Adults With Type 2 Diabetes: A Systematic Review.Cureus · 2026Review
- Comprehensive Review of Gestational Diabetes: Pathophysiology, Pharmacological Management and the Role of Pharmaceutical Care.Current drug safety · 2026Review
- Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study.Pharmacy (Basel, Switzerland) · 2025Article
- Overcoming therapeutic inertia in newly diagnosed type 2 diabetes: Protocol of a randomized, quality improvement trial.Contemporary clinical trials · 2025Article
- Understanding Gaps in the Hypertension and Diabetes Care Cascade: Systematic Scoping Review.JMIR public health and surveillance · 2024Article
- Effect on Diabetes Control in a Resident Clinic Following the Integration of a Clinic Pharmacist.Journal of community hospital internal medicine perspectives · 2024Article
- Racial and Ethnic Disparities in Community-Based Pharmacies: A Scoping Review.Pharmacy (Basel, Switzerland) · 2023Article
- Evaluating Pharmacotherapy Optimization in Pharmacist-Led Management of Type 2 Diabetes Utilizing Continuous Glucose Monitors.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus affects 13% of American adults. To address the complex care requirements necessary to avoid diabetes-related morbidity, the American Diabetes Association recommends utilization of multidisciplinary teams. Research shows pharmacists have a positive impact on multiple clinical diabetic outcomes.
methodsOpen-label randomized controlled trial with 1:1 assignment that took place in a single institution resident-run outpatient medicine clinic. Patients 18-75 years old with type 2 diabetes mellitus and most recent HbA1c ≥9% were randomized to standard of care (SOC) (continued with routine follow up with their primary provider) or to the SOC + pharmacist-managed diabetes clinic PMDC group (had an additional 6 visits with the pharmacist within 6 months from enrollment). Patients were followed for 12 months after enrollment. Data collected included HbA1c, lipid panel, statin use, blood pressure control, immunization status, and evidence of diabetic complications (retinopathy, nephropathy, neuropathy). Intention-to-treat and per-protocol analysis were performed.
resultsForty-four patients were enrolled in the SOC + PMDC group and 42 patients in the SOC group. Average decrease in HbA1c for the intervention compared to the control group at 6 months was - 2.85% vs. -1.32%, (p = 0.0051). Additionally, the odds of achieving a goal HbA1c of ≤8% at 6 months was 3.15 (95% CI = 1.18, 8.42, p = 0.0222) in the intervention versus control group. There was no statistically significant difference in the remaining secondary outcomes measured.
conclusionsAddition of pharmacist managed care for patients with type 2 diabetes mellitus is associated with significant improvements in HbA1c compared with standard of care alone. Missing data during follow up limited the power of secondary outcomes analyses.
trial registrationClinicalTrials.gov , ID: NCT03377127 ; first posted on 19/12/2017.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.